Open Access Research article

The German fibromyalgia consumer reports – a cross-sectional survey

Winfried Häuser12*, Eva Jung12, Brigitte Erbslöh-Möller3, Mechthild Gesmann4, Hedi Kühn-Becker5, Franz Petermann6, Jost Langhorst7, Reinhard Thoma8, Thomas Weiss9, Frederick Wolfe10 and Andreas Winkelmann11

Author Affiliations

1 Department Internal Medicine I, Klinikum Saarbrücken, Saarbrücken, D-66119, Germany

2 Department of Psychosomatic medicine and psychotherapy, Technische Universität München, München, D-81675, Germany

3 Rheumatology Office, Neunkirchen, D-66538, Germany

4 Psychosomatic medicine and pain therapy office, Herford, D- 32049, Germany

5 Psychosomatic medicine and pain therapy office, Zweibrücken, D-66432, Germany

6 Centre of clinical psychology and rehabilitation, Universität Bremen, Bremen, D- 28359, Germany

7 Department Internal Medicine V (Integrative Medicine), Kliniken Essen-Mitte, Universität Essen-Duisburg, Essen, D-45726, Germany

8 Algesiologikum München, München, 80799, Germany

9 Day clinic Mannheim Dr. Weiss, Mannheim, D-68161, Germany

10 National Data Bank for Rheumatic Diseases, Wichita, Kansas and University of Kansas School of Medicine, Wichita, KS, USA

11 Department of Physical Medicine and Rehabilitation, Klinikum der, Universität München, München, D-80336, Germany

For all author emails, please log on.

BMC Musculoskeletal Disorders 2012, 13:74  doi:10.1186/1471-2474-13-74

Published: 18 May 2012



Consumer surveys provide information on effectiveness and side effects of medical interventions in routine clinical care. A report of fibromyalgia syndrome (FMS) consumers has not been carried out in Europe.


The study was carried out from November 2010 to April 2011. Participants diagnosed with FMS rated the effectiveness and side effects of pharmacological and non-pharmacological FMS interventions on a 0 to 10 scale, with 10 being most efficacious (harmful). The questionnaire was distributed by the German League for people with Arthritis and Rheumatism and the German Fibromyalgia Association to their members and to all consecutive FMS patients of nine clinical centers of different levels of care.


1661 questionnaires (95% women, mean age 54 years, mean duration since FMS diagnosis 6.8 years) were analysed. The most frequently used therapies were self-management strategies, prescription pain medication and aerobic exercise. The highest average effectiveness was attributed to whole body and local warmth therapies, thermal bathes, FMS education and resting. The highest average side effects were attributed to strong opioids, local cold therapy, gamma-amino-butyric acid analogues (pregabalin and gabapentin), tramadol and opioid transdermal systems.


The German fibromyalgia consumer reports highlight the importance of non-pharmcological therapies in the long-term management of FMS, and challenges the strong recommendations for drug therapies given by FMS-guidelines.

Fibromyalgia syndrome; Consumer reports; Drugs; Non-pharmacological therapies